Category Archive

Medical Information

Epileptic Syndromes and Visually Induced Seizures

August 8, 2011

Renzo Guerrini and Pierre Genton From Epilepsia, Volume 45 Issue s1 Page 14-18 January 2004 doi:10.1111/j.0013-9580.2004.451011.x URL: http://www.blackwell-synergy.com/doi/full/10.1111/j.0013-9580.2004.451011.x Summary: Seizures induced by photic (or visual) stimuli or photosensitive seizures can be observed in generalized or focal, idiopathic, or symptomatic epilepsies, in progressive neurodegenerative disorders, and even in the context of situation-related (acute symptomatic) seizures. In…

Health Canada updates safety information for Trileptal (oxcarbazepine)

August 5, 2011

Health Canada Endorsed Important Safety Information on TRILEPTAL (oxcarbazepine): Association of TRILEPTAL (oxcarbazepine) with life-threatening dermatological reactions and multi-organ hypersensitivity In April 2005, Novartis Pharmaceuticals Canada Inc. distributed a letter to Canadian healthcare professionals concerning the updated consumer information for Trileptal tablets and oral suspension. Trileptal is used as a monotherapy or adjunctive therapy to…

Health Canada updates safety information on Lamictal (lamotrigine)

August 5, 2011

Health Canada Endorsed Important Safety Information on LAMICTAL (lamotrigine): Important Safety Information Concerning Interactions of the Anti-epileptic Drug Lamictal In September 2004, GlaxoSmithKline Inc. distributed a letter to Canadian healthcare professionals concerning the safety of the anti-epileptic drug, Lamictal. Women who combined Lamictal with their birth control pills  have reported the following: seizures unexpected pregnancies…

U.S. Patients Seeking Medications from Canada

August 5, 2011

U.S. Federal Policy As a general matter, it is illegal to import an unapproved drug into the U.S. However, under Food and Drug Administration’s (FDA) personal importation policy, FDA has authorized its inspectors to use their enforcement discretion to allow U.S. residents to import certain products under certain limited conditions. Under this policy, FDA may…